Download compnay reports

ChangeWave Research: Alzheimer’s and Parkinson’s Disease Survey
November 9, 2004
ChangeWave Research Report:
Alzheimer’s and Parkinson’s Disease Survey
Overview
During the week of October 27 – November 2, 2004, we conducted a survey of Alliance
healthcare members to examine the issues and technologies for addressing both
Alzheimer’s and Parkinson’s disease. A total of 85 healthcare industry members
participated, including 27 doctors who treat patients with Alzheimer’s disease and 22 who
treat patients with Parkinson’s disease. Here’s what we found:
(A) Alzheimer’s Disease
 Alzheimer’s on the Rise. The vast majority of doctors who treat patients with
Alzheimer’s disease (78%) reported seeing an increase in the number of Alzheimer’s
patients over the past year. None of the doctors surveyed reported seeing a decrease.
 Earlier Detection. Fifty-two percent (52%) of doctors who treat Alzheimer's say new
patients are coming in "Earlier" than the historical norm, while 37% say they are coming
in "As They Have in the Past.”
 Most Effective Drugs Currently. Doctors found Aricept (59%) to be the most effective
drug in the treatment of Alzheimer’s, followed by Namenda (44%) and Reminyl (30%).
 Market Share Gainers – Next 12-24 Months. Namenda (41%) is rated by doctors as
the drug positioned to gain the most market share over the next 12-24 months.
Reminyl (30%) came in second, followed by Aricept (22%).
 Most Promising Research and/or Drug Development Trend. We asked respondents
about the most promising trends in Alzheimer's research and drug development today.
MJW5673 writes, "We are gaining a more complete understanding of the complete
series of events that contributes to the disease. This gives more targets for treatment
that, even if they do not cure, can slow progression... A combination of approaches to
treating the disease is likely to be better than one..."
(B) Parkinson’s Disease
 Increase in Parkinson’s Patients. Thirty-seven percent (37%) of doctors who treat
patients with Parkinson’s have seen either a significant or moderate increase in the
number of Parkinson’s patients over the past year, while 64% say they have seen no
change in the number of patients.
Copyright ©2004 ChangeWave Research
All rights reserved.
ChangeWave Research: Alzheimer’s and Parkinson’s Disease Survey
 Earlier Detection. Twenty-three percent (23%) of doctors who treat Parkinson's say
new patients are coming in at an "Earlier" stage of the disease than has typically been
the norm. Only 5% say patients are coming in "Later," while 68% say patients are
coming in "As They Have in the Past."
 Most Promising Treatment Areas - Next Two Years. Neuroprotective Agents (27%)
is seen by doctors as the most promising treatment area in the next two years, followed
by Brain Implants (18%) and Neural Tissue Transplants (14%).
 Most Effective Drugs Currently Prescribed. One-in-two doctors (50%) found
Sinemet (Carbidopa) as the most effective drug currently being prescribed for the
treatment of Parkinson’s. Another 23% found Comtan (Entacapone) to be most
effective.
 Market Share Gainers – Next 12-24 Months. Sinemet (Carbidopa) (18%) tops the list
of drugs for Parkinson’s that doctors believe will gain the most market share over the
next 12-24 months. Comtan (Entacapone) (9%) and Requip (Ropinirole Hydrochloride)
(9%) came in tied for second.
 Most Promising Research and/or Drug Development Trends. Regarding the most
promising trends in research and drug development for Parkinson's today, STE3218
writes, "Parkinson's seems to have more environmental factors (viral or toxin) that
affect progression. Research in these areas seems to be progressing." DJA1158
writes, "There are not any truly ground breaking advances just a series of incremental
advances. No one really stands out."
Interestingly, 18% of respondents cite Stem Cell research as the most promising
research in Parkinson's today.
Bottom Line: According to the survey findings, doctors who treat Alzheimer’s
overwhelmingly report that the number of Alzheimer’s patients has risen over the past
year (78%), and that they are coming in at earlier stages of the disease (52%). Aricept,
Namenda and Reminyl were found to be the most effective drug treatments currently on
the market, and are considered likely to gain the most market share over the next two
years.
The findings also show better than one-in-three doctors (37%) treating Parkinson’s have
seen an increase in the number of patients over the past year, and 23% report patients
are coming in at earlier stages of the disease. Respondents see Sinemet (Caridopa) as
the most effective drug treatment currently being prescribed, and believe it is most likely
to gain market share over the next two years.
The ChangeWave Alliance is a group of 4,900 highly qualified business, technology, and medical professionals in
leading companies of select industries—credentialed professionals who spend their everyday lives working on the
frontline of technological change. ChangeWave surveys its Alliance members on a range of business and investment
research and intelligence topics, collects feedback from them electronically, and converts the information into
proprietary quantitative and qualitative reports.
Helping You Profit From A Rapidly Changing World ™
www.ChangeWave.com
Copyright ©2004 ChangeWave Research
All rights reserved.
2
ChangeWave Research: Alzheimer’s and Parkinson’s Disease Survey
Table of Contents
Summary of Key Findings ............................................................................................ 4
The Findings .................................................................................................................. 5
(A) Alzheimer’s Disease ...................................................................................... 5
(B) Parkinson’s Disease ..................................................................................... 10
ChangeWave Research Methodology ....................................................................... 15
About ChangeWave Research ................................................................................... 16
Copyright ©2004 ChangeWave Research
All rights reserved.
3
ChangeWave Research: Alzheimer’s and Parkinson’s Disease Survey
I. Summary of Key Findings
Parkinson’s Disease
Alzheimer’s
Disease
Increase in Patients over
Past Year
Number of Patients
On the Rise
 Vast majority of doctors
who treat patients with
Alzheimers (78%) report
having seen an increase
in Alzheimer’s patients
over past year. None
have seen a decrease
 37% of doctors who treat
Parkinson’s have seen
either a significant or
moderate increase in the
number of Parkinson’s
patients over the past year.
64% say they have seen
no change in the number of
patients
Earlier Detection
Earlier Detection
 52% of doctors who treat
Alzheimer’s say new
patients are “Coming in
Earlier” than the
historical norm, while
37% say they are
coming in “As They Have
in the Past”
 23% of doctors say
Parkinson’s patients are
coming in at an earlier
stage than has been the
norm. Only 5% say patients
are coming in later
 Another 68% say Patients
are coming in “As They
Have in the Past”
Most Promising
Treatment Areas
 Neuroprotective Agents
(27%)
 Brain Implants (18%)
 Neural Tissue Transplants
(14%)
Drug Treatment
Winners
Alzheimer’s:
Currently Prescribed
 Aricept (59%)
 Namenda (44%)
 Reminyl (30%)
Market Share Gainers –
Next 12-24 Months
 Namenda (41%)
 Reminyl (30%)
 Aricept (22%)
Parkinson’s:
Currently Prescribed
 Sinemet (Carbidopa)
(50%)
 Comtan (Entacapone)
(23%)
Market Share Gainers –
Next 12-24 Months
 Sinemet (Carbidopa) (18%)
 Comtan (Entacapone) (9%)
 Requip (Ropinirole
Hydrochloride) (9%)
Introduction
During the week of October 27 – November 2, 2004, we conducted a survey of Alliance
healthcare members to examine the issues and technologies for addressing both
Alzheimer’s and Parkinson’s disease. A total of 85 healthcare industry members
participated, including 27 doctors who treat patients with Alzheimer’s disease and 22 who
treat patients with Parkinson’s disease.
The findings focus on the two disease areas as follows:
(A) Alzheimer’s Disease
(B) Parkinson’s Disease
Copyright ©2004 ChangeWave Research
All rights reserved.
4
ChangeWave Research: Alzheimer’s and Parkinson’s Disease Survey
II. The Findings
(A) Alzheimer’s Disease
Doctors Who Treat Patients with Alzheimer’s Disease (n=27)
All Other Respondents Working With/Knowledgeable about Alzheimer’s Disease (n=45)
(1) Question Asked: Alzheimer's is a disease associated with aging populations. In
your practice, have you seen an increase in the number of Alzheimer's patients, a
decrease, or has the number of Alzheimer's patients remained the same over the
past year?
Significant Increase in Alzheimer's Patients
Moderate Increase in Alzheimer's Patients
Decrease in Alzheimer's Patients
No Change in the Number of Alzheimer's Patients
Do Not Work in a Practice
Don't Know
Doctors
4%
74%
0%
22%
0%
0%
Alzheimer’s on the Rise. The vast majority of doctors who treat patients with
Alzheimer’s disease (78%) reported seeing an increase in the number of Alzheimer’s
patients over the past year. None of the doctors surveyed reported seeing a decrease.
(2) Question Asked: Over the past year, has your typical new Alzheimer's patient
been coming in earlier, later or at the same stage of the disease as has typically
been the historical norm?
Patients are Coming in Earlier
Patients are Coming in Later
Patients are Coming in as They Have in the Past
Do Not Work in a Practice
Don't Know/No Answer
Doctors
52%
4%
37%
4%
4%
Earlier Detection. Fifty-two percent (52%) of doctors who treat Alzheimer's say new
patients are coming in "Earlier" than the historical norm, while 37% say they are coming
in "As They Have in the Past.”
Copyright ©2004 ChangeWave Research
All rights reserved.
5
ChangeWave Research: Alzheimer’s and Parkinson’s Disease Survey
(3) Question Asked: What do you believe is the most promising trend in research
and/or drug development for Alzheimer's today? (n=49)
Preventive Measures and Identification of Causes
Drug Development
Stem Cell Research
None
Other
22%
18%
16%
10%
18%
Sample of Alliance Member Responses:
(a) Preventive Measures and Identification of Causes (22%)
 BIO9114 writes, "Baby boomers have cared for parents and relatives and are aware of
their propensity to develop AD. They are taking more anti-oxidants and other vitamins
and will seek earlier diagnosis and treatment than the last generation. There have also
been some early but promising drugs developed which may inhibit the formation of
amyloid fibrils."
 LAH6124 writes, "Prevention is the best cure here and hence research focusing on
immunization is very promising."
 MTL7799 writes, "Research directed both at preventing memory loss and identifying
risk factors for the disease."
 COB6520 writes, "Prevention. Alzheimer's has been linked to Polio and other
contaminated vaccinations, aluminum toxicity and stealth pathogens. These are areas
that would pay off if research dollars were directed more at prevention."
 STE3218 writes, "Looking for underlying causes … Medications really only keep mild
symptoms at bay for short periods of time and dramatic improvements are lacking."
 2464180 writes, "Identification of memory genes."
 FSC4718 writes, "Studies of causative factors."
 MJW5673 writes, "We are gaining a more complete understanding of the complete
series of events that contributes to the disease. This gives more targets for treatment
that, even if they do not cure, can slow progression. And slowing progression is
functionally equivalent to cure. A combination of approaches to treating the disease is
likely to be better than one, particularly since the process is likely to vary somewhat in
different individuals. This means that the "space" for products will be larger. Also,
several neurodegenerative diseases (Alzheimer's, Parkinson's ALS, Huntington's, etc.)
seem to have general similarities in regard to mechanism of disease (i.e., they are all
probably aberrant protein folding diseases). Thus, knowledge of and treatments for
one disease will contribute to understanding of and treatments for other diseases."
Copyright ©2004 ChangeWave Research
All rights reserved.
6
ChangeWave Research: Alzheimer’s and Parkinson’s Disease Survey
 FLO8176 writes, "Better animal models (well, better than nothing I suppose). A
validated animal model with a human disease relevant (clinical) endpoint remains to be
found. Some of the treatments aimed at slowing down the progression appear
promising but are difficult to progress."
 KLL5671 writes, "The discovery of an increase of Beta Amyloid in patients with
Alzheimer's and that it involves the nerve processes called the tangles."
(b) Drug Development (18%)
 DJA1158 writes, "The vaccine which is still early stage and several years away from
proven efficacy and safety."
 BUC1834 writes, "Statins, neuroprotective agents."
 SR14084 writes, "Aricept is the most popular tx; however, many more 'naturally'
inclined, have had good results using essential oils and nutritional supplements and
exercise…"
 KES5963 writes, "Vaccines and inhibitors of amyloid deposition."
 8486810 writes, "Exelon being a "bi-modal" approach that might indeed retard
advancement. Aricept has been the "mainstay" treatment."
(c) Stem Cell Research (16%)
 DOC6228 writes, "Stem cell research."
 WSE7249 writes, "Stem cell."
 GHM8270 writes, "Stem cell research and genetic manipulation."
 JES5551 writes, "Disease can be thought of by analogy to faulty electrical circuits. If
neurons die as a result then stem cells could be useful and possibly the only possible
cure."
 MAM7387 writes, "Genetic and stem cell research."
(d) None (10%)
 BTB1963 writes, "None."
 HS06634 writes, "No change."
 KCO6695 writes, "Namenda holds short term promise for patients but nothing that I am
aware of will stop this terrible disease in its tracks."
 WSH1329 writes, "No clear trend yet."
Copyright ©2004 ChangeWave Research
All rights reserved.
7
ChangeWave Research: Alzheimer’s and Parkinson’s Disease Survey
(e) Other (18%)
 SCM5876 writes, "Antibody treatments to remove the proteins that cause the disease."
 DRJ5952 writes, "Cognitive enhancers."
 MIN9289 writes, "Inhibition of plaque formation."
 JSA8571 writes, "To slow the rate of progression of impairment of cognitive function."
 PWG2815 writes, "Calcium EDTA chelation."
 GJI8677 writes, "New generation of therapies."
 GAN7111 writes, "Elan and Wyeth's antibody."
 CAN7667 writes, "Symptom easing."
 GOP2712 writes, "General awareness."
(4) Question Asked: There are a handful of drug treatments currently being
prescribed for Alzheimer's. Which of the following drugs do you find are most
effective in the treatment of Alzheimer's? (Check All That Apply)
Aricept (donepezil hydrochloride)
Namenda (memantine hydrochloride)
Reminyl (galantamine hydrobromide)
Exelon (rivastigmine tartrate)
Cognex (tacrine)
Don't Know
Other
Doctors
59%
44%
30%
15%
11%
15%
19%
Most Effective Drugs Currently. Doctors found Aricept (59%) to be the most effective
drug in the treatment of Alzheimer’s, followed by Namenda (44%) and Reminyl (30%).
(5) Question Asked: And which of the following drug treatments do you believe will
gain the most market share over the next 12-24 months? (Check All That Apply)
Namenda (memantine hydrochloride)
Reminyl (galantamine hydrobromide)
Aricept (donepezil hydrochloride)
Exelon (rivastigmine tartrate)
Cognex (tacrine)
Don't Know
Other
Doctors
41%
30%
22%
11%
7%
22%
7%
Copyright ©2004 ChangeWave Research
All rights reserved.
8
ChangeWave Research: Alzheimer’s and Parkinson’s Disease Survey
Market Share Gainers – Next 12-24 Months. Namenda (41%) is rated by doctors as the
drug positioned to gain the most market share over the next 12-24 months. Reminyl
(30%) came in second, followed by Aricept (22%).
(6) Question Asked: What about off-label drug treatments for Alzheimer's? Do you
know of any off-label drug treatments for Alzheimer's that are gaining industry
acceptance?
Sample of Alliance Member Responses:
 BUC1834 writes, "Folic acid/b vitamins (foltx/cerefolin), maybe statins."
 PWG2815 writes, "CaEDTA works but is not accepted by industry or main stream
medicine because it is too difficult to make money."
 LST2748 writes, "Memantine for early disease."
 GJI8677 writes, "Modafinil."
 MJW5673 writes, "Merck has shown interest in a potential treatment for lymphoblastic
leukemia that involves an inhibitor of gamma secretase (being developed at Harvard,
not yet in clinical trials but may be close). The leukemia does not affect very many
people, but inhibiting the secretase could be an off-label treatment for Alzheimer's. The
secretase is believed to be involved in processing of beta-amyloid protein, an early step
in the series of events believed to result in Alzheimer's."
 DJA1158 writes, "No. A better question is are AD drugs being used off label for other
conditions associated with memory loss or even as ‘cosmetic neurology’ or for
‘performance enhancement.’ The answer unequivocally is yes with all drugs being
used, probably Aricept the most."
 RAF5760 writes, "Huperzine; but doubt it is widely used."
Copyright ©2004 ChangeWave Research
All rights reserved.
9
ChangeWave Research: Alzheimer’s and Parkinson’s Disease Survey
(B) Parkinson's Disease
Doctors Who Treat Patients with Parkinson’s Disease (n=22)
All Other Respondents Working With/Knowledgeable About Parkinson’s Disease (n=52)
(7) Question Asked: In your practice, have you seen an increase in the number of
Parkinson's patients, a decrease, or has the number of Parkinson's patients
remained the same over the past year?
Significant Increase in Parkinson's Patients
Moderate Increase in Parkinson's Patients
Decrease in Parkinson's Patients
No Change in the Number of Parkinson's Patients
Do Not Work in a Practice
Don't Know/No Answer
Doctors
5%
32%
0%
64%
0%
0%
Increase in Parkinson’s Patients. Thirty-seven percent (37%) of doctors who treat
patients with Parkinson’s have seen either a significant or moderate increase in the
number of Parkinson’s patients over the past year, while 64% say they have seen no
change in the number of patients.
(8) Question Asked: Over the past year, has your typical new Parkinson's patient
been coming in earlier, later or at the same stage of the disease as has typically
been the historical norm?
Patients are Coming in Earlier
Patients are Coming in Later
Patients are Coming in as They Have in the Past
Do Not Work in a Practice
Don't Know/No Answer
Doctors
23%
5%
68%
0%
5%
Earlier Detection. Twenty-three percent (23%) of doctors who treat Parkinson's say new
patients are coming in at an "Earlier" stage of the disease than has typically been the
norm. Only 5% say patients are coming in "Later," while 68% say patients are coming in
"As They Have in the Past."
Copyright ©2004 ChangeWave Research
All rights reserved.
10
ChangeWave Research: Alzheimer’s and Parkinson’s Disease Survey
(9) Question Asked: What do you believe is the most promising trend in research
and/or drug development for Parkinson's today? (n=34)
Preventive Measures/Identification of Causes
Stem Cells
Surgery
Drug Development
None
Other
21%
18%
15%
12%
3%
12%
Sample of Alliance Member Responses:
(a) Preventive Measures and Identification of Causes (21%)
 LST2748 writes, "Basic Research re: Causation and possibility of stem cell research to
develop therapy."
 SCM5876 writes, "Research to understand the cause of the neuronal cell death."
 STE3218 writes, "Same argument as for Alzheimer’s. Parkinson's seems to have more
environmental factors (viral or toxin) that affect progression. Research in these areas
seems to be progressing."
 DJA1158 writes, "There are not any truly ground breaking advances just a series of
incremental advances. No one really stands out."
(b) Stem Cells (18%)
 DOC6228 writes, "Stem cell research."
 SSL1154 writes, "Stem Cell."
 MAM7387 writes, "Stem-cell RX."
 DOC4023 writes, "Stem cell/gene therapy."
(c) Surgery (15%)
 MIN9289 writes, "Transplant involving dopamine-producing cells or a synthetic variant."
 GOP2712 writes, "Surgery."
 TDA3174 writes, "There are some new surgeries for selective Parkinson points."
 FER6743 writes, "My brother had a brain device implanted that along with the meds
seemed to help."
 TIN7270 writes, "Brain ‘Pacemaker’."
Copyright ©2004 ChangeWave Research
All rights reserved.
11
ChangeWave Research: Alzheimer’s and Parkinson’s Disease Survey
(d) Drug Development (12%)
 8486810 writes, "Better, longer-acting meds."
 BUC1834 writes, "Neuroprotective agents."
(e) Other (12%)
 BTB1963 writes, "Deep Brain stimulation for severe Parkinson’s."
 GJI8677 writes, "New generation of therapies."
 EGF6017 writes, "Genetic engineering, transfecting the brain cell so that they increase
their production of dopamine, neuroprotective or neurotrophic factors."
(10) Question Asked: There is a tremendous amount of research underway to treat
Parkinson's symptoms. Which of the following treatment areas do you believe hold
the most promise in the next two years?
Doctors
Neuroprotective Agents
Brain Implants
Neural Tissue Transplants
Neurotrophic Proteins
Genetic Engineering
Don't Know/No Answer
Other
27%
18%
14%
5%
0%
32%
5%
Total
Respondents
19%
19%
11%
9%
9%
30%
3%
Most Promising Treatment Areas - Next Two Years. Neuroprotective Agents (27%) is
seen by doctors as the most promising treatment area in the next two years, followed by
Brain Implants (18%) and Neural Tissue Transplants (14%).
Copyright ©2004 ChangeWave Research
All rights reserved.
12
ChangeWave Research: Alzheimer’s and Parkinson’s Disease Survey
(11) Question Asked: There are several drug treatments currently being prescribed
for Parkinson's Disease. Which of the following drugs do you find are most
effective in the treatment of Parkinson's? (Check All That Apply)
Sinemet (carbidopa)
Comtan (entacapone)
Parlodel (bromocriptine)
Mirapex (pramipexole dihydrochloride)
Requip (ropinirole hydrochloride)
Eldepryl (selegiline hydrochloride) (AKA deprenyl)
Permax (pergolide)
Symmetrel (amantadine)
Laradopa (levadopa)
Dostinex (cabergoline)
Tasmar (tolcapone)
Lioresal (baclofen)
Don't Know
Other
Doctors
50%
23%
18%
18%
18%
14%
14%
14%
9%
5%
0%
0%
27%
5%
Most Effective Drugs Currently Prescribed. One-in-two doctors (50%) found Sinemet
(Carbidopa) as the most effective drug currently being prescribed for the treatment of
Parkinson’s. Another 23% found Comtan (Entacapone) to be most effective.
(12) Question Asked: And which of the following drug treatments do you believe
will gain the most market share over the next 12-24 months? (Choose No More
Than Two)
Sinemet (carbidopa)
Comtan (entacapone)
Requip (ropinirole hydrochloride)
Mirapex (pramipexole dihydrochloride)
Permax (pergolide)
Symmetrel (amantadine)
Dostinex (cabergoline)
Laradopa (levadopa)
Tasmar (tolcapone)
Eldepryl (selegiline hydrochloride) (AKA deprenyl)
Lioresal (baclofen)
Parlodel (bromocriptine)
Don't Know
Other
Doctors
18%
9%
9%
5%
5%
5%
5%
0%
0%
0%
0%
0%
55%
9%
Copyright ©2004 ChangeWave Research
All rights reserved.
13
ChangeWave Research: Alzheimer’s and Parkinson’s Disease Survey
Market Share Gainers – Next 12-24 Months. Sinemet (Carbidopa) (18%) tops the list of
drugs for Parkinson’s that doctors believe will gain the most market share over the next
12-24 months. Comtan (Entacapone) (9%) and Requip (Ropinirole Hydrochloride) (9%)
came in tied for second.
(13) Question Asked: What about off-label drug treatments for Parkinson's? Do you
know of any off-label drug treatments for Parkinson's that are gaining industry
acceptance?
Sample of Alliance Member Responses:
 WSE7249 writes, "Neuro science labs makes amino acid supplements that seem to
work."
 KES5963 writes, "Coenzyme Q10 in high doses."
 COB6520 writes, "High dose vitamin therapy."
Copyright ©2004 ChangeWave Research
All rights reserved.
14
ChangeWave Research: Alzheimer’s and Parkinson’s Disease Survey
III. ChangeWave Research Methodology
This report presents the findings of the latest ChangeWave Alliance survey on
Alzheimer’s and Parkinson’s Disease conducted October 27, 2004 – November 2, 2004.
The survey was for Alliance healthcare industry members knowledgeable about
Alzheimer’s and/or Parkinson’s Disease. A total of 85 healthcare industry members
participated, including 27 doctors who treat patients with Alzheimer’s disease and 22
doctors who treat patients with Parkinson’s disease.
The Alliance’s proprietary research and business intelligence gathering system is based
upon the systematic gathering of valuable business and investment information directly
over the Internet from accredited members.
ChangeWave surveys its Alliance members on a range of business and investment
research and intelligence topics, collects feedback from them electronically, interprets
and reconciles the information in a cohesive manner and converts the information into
valuable quantitative and qualitative reports.
The Alliance has assembled its membership team from senior technology and business
executives in leading companies of select industries. Nearly 3 out of every 5 members
(58%) have advanced degrees (e.g., Master’s or Ph.D.) and 94% have at least a fouryear bachelor’s degree.
The business and investment intelligence provided by the Alliance provides a real-time
view of companies, technologies and business trends in key market sectors, along with
an in-depth perspective of the macro economy – well in advance of other available
sources.
Copyright ©2004 ChangeWave Research
All rights reserved.
15
ChangeWave Research: Alzheimer’s and Parkinson’s Disease Survey
IV. About ChangeWave Research
ChangeWave Research, a subsidiary of Phillips Investment Resources, LLC, identifies
and quantifies "change" in industries and companies through surveying a network of
thousands of business executives and professionals working in more than 20 industries.
ChangeWave has a very unique asset in its 4,900-member Alliance. We have assembled
our membership team from a broad cross section of more than 20 vertical markets such
as telecom, semiconductors, data storage, and biotechnology, along with a wide range of
professional disciplines including CIOs, IT managers and programmers, executive
management, scientists, engineers and sales personnel.
The ChangeWave Alliance is composed of senior technology and business executives in
leading companies - credentialed professionals who spend their everyday lives working
on the frontline of technological change.
This proprietary research and business intelligence gathering system provides a real-time
view of companies, technologies and business trends in key market sectors along with an
in-depth perspective of the macro economy - well in advance of other available sources.
ChangeWave surveys its 4,900 Alliance members on a wide range of investment
research topics and converts the findings into valuable investment and business
intelligence reports. ChangeWave delivers its products and services on the Web at
www.ChangeWave.com.
ChangeWave Research does not make any warranties, express or implied, as to
results to be obtained from using the information in this report. Investors should
obtain individual financial advice based on their own particular circumstances
before making any investment decisions based upon information in this report.
For More Information:
ChangeWave Research
9420 Key West Avenue
Rockville, MD 20850
USA
Telephone: 301-279-4200
Fax: 301-610-5206
www.ChangeWave.com
[email protected]
Helping You Profit From A Rapidly Changing World ™
www.ChangeWave.com
Copyright ©2004 ChangeWave Research
All rights reserved.
16